Epoetin Alfa
Recombinant Human Erythropoietin (rHuEPO)
Also known as: Epogen · Procrit · Eprex · NeoRecormon · rHuEPO · epoetin alfa · r-HuEPO-alpha · Epoetin beta · rhEPO · Recombinant human erythropoietin
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Dosing by species
🌎 NA — North America🌍 EU — Europe
Dogs
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Adjunctive therapy for anemia associated with endstage renal disease | Initially, 100 Units/kg SC 3 times weekly, until the bottom of the target hematocrit range of 37-45% is attained. Once attained, change to twice weekly. As hematocrit approaches upper target, reduce to once weekly. Maintenance generally 75-100 Units/kg SC 1-2 times weekly. | SC | 3 times weekly initially | Ongoing | 🌎 NA |
| Adjunctive therapy for anemia associated with endstage renal disease | Initially, 48.4-145 Units/kg SC three times a week. Most dogs should be started at 97 Units/kg SC 3 times a week. | SC | 3 times a week | Ongoing | 🌎 NA |
- Adjunctive therapy for anemia associated with endstage renal disease: A lower initial dosage of 50-100 Units/kg 3 times weekly may be used. Iron supplementation required.
- Adjunctive therapy for anemia associated with endstage renal disease: Monitor hematocrit weekly until target 37-45% is reached, then decrease to two times weekly. Oral iron supplements recommended.
Cats
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Adjunctive therapy for anemia associated with endstage renal disease | Initially, 100 Units/kg SC 3 times weekly (or 48.4-145 Units/kg SC 3 times a week). | SC | 3 times weekly | Ongoing | 🌎 NA |
| Anemia associated with endstage renal disease (PCV <20%) | 75-100 Units/kg SC three times a week until PCV is in the low normal range (35%), then reduce dose and frequency to 50-75 Units/kg two times per week. | SC | 3 times a week initially | Ongoing | 🌎 NA |
| Problematic clinical signs and PCV <20% | Initially, 100 Units/kg SC 3 times per week. | SC | 3 times per week | Ongoing | 🌎 NA |
- Adjunctive therapy for anemia associated with endstage renal disease: Target hematocrit is 30-40%.
- Anemia associated with endstage renal disease (PCV <20%): Administer iron at start of regime and until appetite is good.
- Problematic clinical signs and PCV <20%: Provide oral supplementation with ferrous sulfate (5-50 mg per cat per day). Reduce to twice per week when target PCV (30-40%) is reached.
Small Mammals
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Anemia (Rabbits) | 50-150 Units/kg SC every 2-3 days until PVC is normal; then once weekly (q7 days) for at least 4 weeks | SC | every 2-3 days initially | at least 4 weeks maintenance | 🌎 NA |
Ferrets
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Anemia | 50-150 Units/kg IM 3 times weekly; may decrease to once weekly if RBC indices are significantly improved | IM | 3 times weekly | Ongoing | 🌎 NA |
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Epoetin alfa is a biosynthetic form of the glycoprotein human hormone erythropoietin (rHuEPO). It is primarily used in veterinary medicine to treat non-regenerative anemia associated with chronic renal failure (CRF) in dogs and cats.
Because it is a human recombinant protein, its use in companion animals carries a significant risk (20-70% incidence) of inducing anti-erythropoietin autoantibodies. These antibodies can cross-react with the animal's own endogenous erythropoietin, leading to profound, transfusion-dependent refractory anemia. Consequently, many clinicians reserve epoetin alfa as a "last ditch effort" when the packed cell volume (PCV) drops into the teens.
Clinical Pearl: Patients receiving epoetin alfa almost universally require concurrent iron supplementation to support the sudden increase in red blood cell production.
Mechanism of action
Erythropoietin is an endogenous hormone primarily produced by the kidneys that regulates erythropoiesis.
- Receptor Binding: Epoetin alfa binds to erythropoietin receptors on the surface of committed erythroid progenitor cells in the bone marrow.
- Proliferation & Differentiation: This binding activates intracellular signaling pathways (such as JAK2/STAT5) → stimulates the survival, proliferation, and differentiation of red cell precursors.
- Reticulocyte Release: It also accelerates the release of reticulocytes from the bone marrow into the systemic circulation, ultimately increasing the hematocrit and hemoglobin levels.
Safety & warnings
Contraindications
- Uncontrolled hypertension
- Hypersensitivity to epoetin alfa
- Formation of significant autoantibodies with prior treatment
- Equines (not recommended for use)
Adverse effects
- Autoantibody formation (leading to refractory anemia)
- Systemic hypertension
- Vomiting
- Seizures
- Uveitis
- Iron depletion
- Local reactions at injection sites
- Fever
- Arthralgia
- Mucocutaneous ulcers
- Polycythemia (with chronic overdosage)
Precautions
Therapy should be started with caution or withheld until corrected in animals with moderate to severe hypertension or iron deficiency.
Autoantibody Risk: Up to 30% of patients may develop antibodies significant enough to cause profound anemia and arrestment of erythropoiesis. A bone marrow aspirate showing a myeloid:erythroid ratio >6 predicts significant autoantibody formation and contraindicates further therapy. Discontinue therapy if polycythemia, fever, anorexia, joint pain, cellulitis, or cutaneous/mucosal ulceration occurs.
Drug interactions
May increase the sensitivity of erythroid progenitors; safety of this combination is not fully determined.
Concurrent use with EPO can decrease bleeding times.
Has been demonstrated to reduce the renal tubular excretion of EPO; clinical significance remains unclear.
Synergistic/Required; EPO increases demand for iron to synthesize hemoglobin for new RBCs
Monitoring
- Hematocrit / PCV (weekly to every other week initially, then every 1-2 months)
- Blood Pressure (at least monthly initially)
- Renal Function Status
- Iron status (serum iron, TIBC)
- RBC indices
Pharmacokinetics
Absorption
Absorbed only after parenteral administration.
Distribution
It is unclear whether the drug crosses the placenta or enters milk.
Metabolism
The drug's metabolic fate is unknown.
Elimination
In patients with chronic renal failure, half-lives are prolonged approximately 20% over those with normal renal function.
Overdose
Acute overdoses appear to be relatively free of adverse effects. Single doses of up to 1600 Units/kg in humans demonstrated no signs of toxicity.
Chronic overdoses may lead to polycythemia or other adverse effects. Cautious phlebotomy may be employed should polycythemia occur.
Available products
Formulations
- Solution for Injection
Human-labeled
- Epoetin Alfa Solution for Injection: 2000 Units/mL, 3000 Units/mL, 4000 Units/mL, 10,000 Units/mL, 20,000 Units/mL and 40,000 Units/mL in single-dose and multidose vials (Epogen®, Procrit®)
Regulatory status
POM (Prescription Only Medicine). Approved for human use, used off-label in veterinary medicine.
POM (Prescription Only Medicine). Approved for human use, used off-label in veterinary medicine.
No regulatory data for: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Store in the refrigerator (2-8°C); do not freeze. Do not shake the solution as denaturation of the protein with resultant loss of activity may occur. Protect from light. Because the solution contains no preservatives, the manufacturer recommends using each vial only as a single use.
Client information
- Administration: If giving injections at home, ensure you have been properly trained by your veterinary team on subcutaneous injection techniques.
- Storage: Keep the medication in the refrigerator (2-8°C). Do not freeze and do not shake the vial, as shaking can destroy the active protein.
- Monitoring: Keep all scheduled appointments for blood tests. Frequent monitoring of red blood cell counts (PCV) and blood pressure is critical.
- Warning Signs: Contact your veterinarian immediately if your pet becomes increasingly lethargic, weak, or loses their appetite, as this could indicate a dangerous immune reaction (autoantibody formation) causing the anemia to worsen.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.